The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Has Tecentriq earned a role in treatment of triple-negative breast cancer?

Here is what experts say

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Daniel HayesStuart B. Padnos Professor of Breast Cancer Research,University of Michigan Rogel Cancer Center

Because we have been siloed into tissue-of-origin treatment bins (melanoma, lung, colorectal, breast, etc) over the last 100 or more years, we have applied these therapies based more on where the cancer was derived than on the biology of the cancer itself.

Obviously, the field of immune-oncology has been one of the great success stories in our field over the last five years, based on our molecular understanding of the mechanisms of immune tolerance (or checkpoints) and how to disrupt that. Not only has ASCO declared Checkpoint Inhibition (as well as cellular-based immunotherapy) the “Advance of the Year,” the Nobel Committee awarded this year’s Prize to Drs. Allison and Honjo for their fabulous observations that led to these great breakthroughs.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

Saving Western Kenya’s pediatric blood cancer patients
How flow cytometry is changing the diagnostic landscape

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
By Samuel (Tony) Boova, Eda Holl, LaToya Montgomery, Steve Kussick, Nicholas Kigen, Gilbert Olbara, Festus Muigai Njuguna, Terry Vik and Teresa Loile Lotodo
ClinicalTrials & Tribulations

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
By Enrique Velazquez-Villarreal
Sponsored

The long life of a clinical trial
How JCO sustains landmark oncology research

In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 
By Journal of Clinical Oncology
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account